Skip to content

Study on the second development of Zhenyuan Capsule in the treatment of double heart disease

Study on the second development of Zhenyuan Capsule in the treatment of double heart disease

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100041994
Enrollment
Unknown
Registered
2021-01-12
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

double heart disease

Interventions

Sponsors

China Japan Union Hospital of Ji Lin University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Coronary heart disease: include stable Angina (SAP), unstable Angina (UA) , Acute non-ST segment elevation myocardial infarction (NSTEMI) , Acute St Segment Elevation Myocardial Infarction (Stemi). SAP DIAGNOSTIC CRITERIA: A diagnosis can be established on the basis of typical seizure characteristics and signs, remissions after rest or Nitroglycerin, in combination with age and the presence of other risk factors for coronary heart disease, except Angina caused by other diseases. Mental Illness: DIAGNOSTIC CRITERIA FOR ANXIETY: Hama score >= 14; Diagnostic criteria for depression: Hamd Score >= 8; SDS score >= 53; Age: 18 to 75 years old, sex is not limited; Patients and their families volunteered for the trial and were able to sign informed consent forms. During the attack, the ECG showed that ST segment was depressed, t wave was flat or inverted, and recovered gradually within a few minutes after the attack. UA/NSTEMI DIAGNOSTIC CRITERIA: Typical Angina symptoms, typical ISCHEMIC ECG changes (new or transient ST segment depression >= 0.1 MV, or t wave inversion. The diagnosis of atypical episodes depends on observing the effects of Nitroglycerin and changes in the electrocardiogram during the episode.>= 0.2 MV). And Myocardial Injury Markers (CTNT, cTnI or CK-MN) were measured. STEMI: refers to an increase and/or decrease in Serum Cardiac Troponin (cTn) in acute myocardial injury at least once above the upper normal limit (99 percentile of the upper reference value) and clinical evidence of acute myocardial ISCHEMIA, including: (1) Acute Myocardial ischemia symptoms; (2) New ISCHEMIC ECG changes; (3) new pathological q waves; (4) new imaging evidence of viable myocardial loss or regional wall motion abnormalities; (5) coronary artery thrombosis was confirmed by coronary angiography or intracavitary imaging.

Exclusion criteria

Exclusion criteria: 1. Use of psychoactive drugs recently; 2. Patients with rheumatic heart disease, congenital heart defect, cardiomyopathy, pulmonary heart disease, hypertensive heart disease, senile valvular disease, Arrhythmia and other heart diseases; 3. NYHA Class IV CARDIAC function; 4. Women who plan to have or have already had a pregnancy and women who are breastfeeding; 5. Understanding, cognitive dysfunction and so on can not cooperate with the questionnaire survey; 6. Drug allergy; 7. Severe Liver and kidney dysfunction; 8. The researchers don't think it was appropriate for the participants.

Design outcomes

Primary

MeasureTime frame
HAMA score;HAMD score;SDS score;blood glucose;blood lipid;liver function test;renal function test;CRP;IL-1;IL-6;TNF-a;CPET;Echo;MRI;

Countries

China

Contacts

Public ContactMeng Fanbo

China Japan Union Hospital of Ji Lin University

mengfb@jlu.edu.cn+86 15948346855

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026